INTRODUCTION
Previous research estimates the lifetime prevalence of compulsive sexual behaviour (CSB) in individuals with Parkinson's disease (PD) to be 2.7%. CSB has also been associated with male gender and earlier onset of PD. 1 Although both dopamine agonists (DAs) and, to a lesser extent, levodopa have been associated with impulsive compulsive behaviours (ICBs), 2 it is still unclear whether higher levodopa doses are a risk factor for the development of CSB in patients with PD.
METHODS
Patients with ICBs were identified from a database of individuals with PD and ICBs who were seen at the National Hospital for Neurology and Neurosurgery, Queen Square, London, UK, and who had participated in three previous research projects over an 8-year period (from 2008 to 2016). All the ICB cases were recruited to research studies from PD clinics at the National Hospital and selected due to the reporting of ICBs. All cases underwent a thorough clinical investigation as well as a detailed semistructured interview conducted by one of the authors. Hospital notes were reviewed by a movement disorder specialist (PMB) for clinical and demographic data. Levodopa equivalent daily dose (LEDD) was calculated according to previously published guidelines. 3 Data were analysed using the software SPSS V.24.
RESULTS
In total, 128 patients with PD For statistical analysis, we divided the cohort into two groups based on the presence of CSB: CSB + (n=55) and CSB − (n=56). The proportion of male individuals was higher in the CSB + group (P<0.001), and these individuals developed ICBs at younger age (P=0.02) (table 1) .
We did not find any differences between groups in the proportion of patients using levodopa, DAs, monoamine oxidase inhibitors (MAOi), amantadine or catechol-O-methyl transferase inhibitors (COMTi). Nine patients had not been exposed to DAs, three with CSB and six without. The CSB + group was using a higher dose of dopaminergic treatment and levodopa as measured by total LEDD (P=0.014), levodopa daily dose (P=0.043), combined levodopa and COMTi LEDD (P=0.039) and isolated COMTi LEDD (P=0.026). DA LEDD (P=0.802) and MAOi LEDD (P=0.934) were similar between groups. Multiple ICBs were present in 48.2% of individuals without and 76.3% of individuals with CSB (P=0.002) (table 1).
The number of patients with dopamine dysregulation syndrome (DDS) did not differ between the groups (P=0.659), suggesting that the higher dose of levodopa in the CSB + group was not being driven by a higher proportion of dysregulators (table 1) .
DISCUSSION
CSB was the most frequently identified ICB in our cohort, affecting almost 50% of people with PD-associated ICBs. We report, for the first time, that PD patients with CSB tend to develop this abnormal PostScript behaviour at an earlier age and are more likely to develop multiple ICBs compared with PD patients with other ICBs.
Another novel finding is that patients with CSB were on higher doses of dopaminergic treatment as measured in LEDD. DA and MAOi dose, and the proportion of patients using DA, amantadine and MAOi did not differ between groups. However, patients with CSB were using a higher levodopa daily dose and higher COMTi doses than patients without CSB, although the proportion of patients using COMTi did not differ between groups. This suggests that higher dopaminergic stimulation, particularly higher doses of levodopa, is a risk factor for the development of CSB. It is likely that higher doses of COMTi are not directly related to ICBs but are rather contributing to excessive dopaminergic stimulation by increasing the bioavailability of levodopa. This is corroborated by the fact that only half of the patients were using COMTi.
The association of abnormal sexual behaviour and levodopa was reported in the early days of levodopa use, years before DAs started being used for PD. Barbeau and colleagues treated 80 patients with PD with an average dose of 4.8 g of levodopa per day and reported that at least four males developed an increase in libido. 4 Although the main risk factor for the development of impulse controls disorders in PD is the use of DAs, 2 levodopa has been found to be an important contributor to the development of ICBs in patients with PD receiving treatment with DAs. 5 Interestingly, despite finding that patients with CSB were on higher doses of levodopa, the proportion of other types of ICBs was similar between groups, indicating that even though higher levodopa doses are associated with CSB and DDS, these abnormal behaviours are not more likely to occur together.
By including only patients that participated in previous research projects, it is possible that we have missed patients with ICBs that were diagnosed during a regular outpatient's appointment. However, since we were interested in assessing the prevalence of CSB among patients with established ICBs we believe this approach minimised the possibility of including false positives.
CONCLUSION
The data from this study suggest that CSB is more frequent in males and tend to appear earlier than other ICBs. CSB may be the most frequent ICB associated with PD. Furthermore, patients with CSB are more likely to develop multiple ICBs. When compared with other types of ICBs, this behavioural addiction appears to be driven by higher levodopa doses. Data from larger studies are needed to confirm these novel findings. 
